Antitumor activity of histone deacetylase inhibitor trichostatin a in osteosarcoma cells

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1395-1399

  Cheng, Dong Dong ^a   Yang, Qing Cheng ^a   Zhang, Zhi Chang ^a   Yang, Cui Xia ^a   Liu, Yi Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Invasiveness; Osteosarcoma; Trichostatin A

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LIPOCORTIN 5; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROLIFERATION; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANNEXIN A5; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NEOPLASM INVASIVENESS; OSTEOSARCOMA;

EID: 84873054458     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1395     Document Type: Article

References (20)

1. Aquerreta I, Aldaz A, Giraldez J, Sierrasesumaga L (2004). Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatr Blood Cancer, 42, 52-8.
2. Chiba T, Yokosuka O, Fukai K, et al (2004). Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology, 66, 481-91.
3. Donadelli M, Costanzo C, Faggioli L, et al (2003). Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog, 38, 59-69.
4. Finnin MS, Donigian JR, Cohen A, et al (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-93.
5. Ghizzoni M, Haisma HJ, Maarsingh H, Dekker FJ (2011). Histone acetyltransferases are crucial regulators in NF-γB mediated inflammation. Drug Discov Today, 16, 504-11.
6. Hirose T, Sowa Y, Takahashi S, et al (2003). p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene, 22, 7762-73.
7. Kim MS, Kwon HJ, Lee YM, et al (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med, 7, 437-43.
8. Kim Y, Park H, Lim Y, et al (2003). Decreased syndecan-2 expression correlates with trichostatin-A inducedmorphological changes and reduced tumorigenic activity in colon carcinoma cells. Oncogene, 22, 826-30.
9. Li MH, Miao ZH, Tan WF, et al (2004). Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res, 10, 8266-74.
10. Liu LT, Chang HC, Chiang LC, Hung WC (2003). Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res, 63, 3069-72.
11. Loidl P, Grobner P (1987). Postsynthetic acetylation of histones during the cell cycle: a general function for the displacement of histones during chromatin rearrangements. Nucleic Acids Res, 15, 8351-66.
12. Marks PA, Richon VM, Breslow R, Rifkind RA (2001). Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol, 13, 477-83.
13. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.
14. Muller M, Strand S, Hug H, et al (1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest, 99, 403-13.
15. Sowa Y, Orita T, Minamikawa S, et al (1997). Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun, 241, 142-50.
16. Strait KA, Dabbas B, Hammond EH, et al (2002). Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther, 1, 1181-90.
17. Vigushin DM, Ali S, Pace PE, et al (2001). Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res, 7, 971-6.
18. Williams RJ (2001). Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs, 10, 1571-3.
19. Wolffe AP, Guschin D (2000). Review: chromatin structural features and targets that regulate transcription. J Struct Biol, 129, 102-22.
20. Yoshida M, Horinouchi S, Beppu T (1995). Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays, 17, 423-30.